Global Biologic Drug Product Contract Manufacturer Quality Benchmarking Report 2021: Analysis of 382 Service Encounters from 110 Respondents – ResearchAndMarkets.com

March 1, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Biologic Drug Product Contract Manufacturer Quality Benchmarking (4th Edition)” report has been added to ResearchAndMarkets.com’s offering.

This Biologic Drug Product Contract Manufacturing Quality Benchmarking report brings with it a wealth of knowledge and information created with two goals in mind, help biopharmaceutical companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies.

This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 23 performance attributes specific to outsourced drug product manufacturing. In this Consumer Reports-style analysis, the report presents data on 382 service encounters from 110 respondents who have been involved in outsourced drug product projects in the past 18 months.

What You Will Learn:

Drug developers:

  • Make a more educated purchase of CMO services by understanding which manufacturers best fit your company’s needs in addition to how individual CMOs have measured up to sponsor-peer expectations on similar projects
  • Uncover which CMO attributes drive outsourcing partner selection for outsourced biologic drug product manufacturing as well as which CMO attributes have gained importance over the past 12 months among industry peers
  • Gain insight into CMO customer loyalty, an index based on customer satisfaction, willingness to recommend, and likelihood to use again, along with verbatim responses from outsourcers regarding their experiences with specific CMOs

Contract Manufacturers:

  • Understand your company’s competitive positioning as well as delivery strengths and weaknesses and use this information to develop targeted messaging on true areas of strength
  • Compare your company’s performance against its competitors across 23 performance metrics specific to outsourced drug product manufacturing and related services
  • Gain insight into drug developers’ outsourcing preferences and practices with respect to CMO selection and CMO preference for outsourced biologic drug product manufacturing

Major Topics:

  • Outsourcing Philosophies and Practices
  • CMO Selection Drivers
  • CMO Perceptions and Interactions
  • CMO Performance and Loyalty
  • Biologic Drug Product CMO Competitive Landscape
  • Company Service Quality Profiles
  • Study Data

Key Topics Covered:

1. Outsourcing Philosophies and Practices

  • Primary Section Takeaways
  • Outsourced Manufacturing Activities
  • Outsourcing Drivers
  • Outsourcing Drivers by Company Size
  • Preferred Providers
  • Number of Preferred Providers
  • Outsourcing Models

2. CMO Selection Drivers

  • Primary Section Takeaways
  • Most Important CMO Attributes
  • CMO Attributes Gaining Importance

3. CMO Perceptions and Interactions

  • Primary Section Takeaways
  • CMO Familiarity
  • CMO Leaders – Unprompted
  • CMO Leaders – Prompted
  • Received Proposals
  • CMO Use
  • CMO Preference
  • CMO Preference Among Users
  • CMO Cost Perceptions
  • Summary Table

4. CMO Performance and Loyalty

  • Primary Section Takeaways
  • A Note on Performance Calculations
  • Performance Across Service Providers
  • CMO Performance: Delivery Factors
  • CMO Performance: Organization Factors
  • CMO Performance: Capabilities Ratings
  • CMO Performance: Staff Characteristics
  • CMO Performance: Service Capabilities
  • CMO Loyalty
  • CMO Loyalty: 3-Year Rolling Average

5. Biologic Drug Product CMO Competitive Landscape

6. Company Service Quality Profiles

7. Study Data

  • Outsourced Manufacturing Activities
  • Outsourcing Drivers
  • Outsourcing Models
  • Use of Preferred Providers
  • Number of Preferred Providers
  • Large Molecule Product Offering
  • Large vs. Small Molecule Outsourcing
  • CMO Selection Attributes
  • CMO Selection Attributes Gaining Importance
  • CMO Leaders – Unprompted
  • Other Responses 1%
  • CMO Familiarity
  • CMO Leaders – Prompted
  • Received Proposals
  • CMO Use
  • CMO Preference
  • CMO Cost Perceptions
  • CMO Drill-downs

    • AbbVie Contract Manufacturing
    • Aji Bio-Pharma
    • Alcami
    • AMRI
    • Baxter BioPharma Solutions
    • Boehringer Ingelheim
    • Carbogen Amcis
    • Catalent
    • Celltrion
    • Dr. Reddy’s CPS
    • Emergent Biosolutions
    • Famar
    • Fareva
    • FujiFilm Diosynth
    • GSK Contract Manufacturing
    • Hetero
    • IDT Biologika
    • Jubilant HollisterStier
    • Just – Evotec Biologics
    • Lonza
    • LSNE Contract Manufacturing
    • Millipore Sigma
    • Nitto Avecia Pharma Services
    • Novasep
    • Patheon, by Thermo Fisher Scientific
    • Pfizer CentreOne
    • Pii
    • Piramal Pharma Solutions
    • Recipharm
    • Rentschler
    • Samsung BioLogics
    • Sandoz
    • Sanofi Active Ingredients, formerly CEPiA Sanofi
    • Siegfried
    • Therapure BioPharma
    • Vetter
    • Wuxi Biologics
  • CMO Satisfaction Rating Explanations

8. Demographics

  • Company Type
  • Headquarters Location
  • Office Location
  • Job Title
  • Decision-making Responsibility
  • Biologic Drug Product Outsourcing
  • Contract Manufacturing Responsibilities
  • Involvement in Outsourced Manufacturing
  • Contract Manufacturing Involvement
  • Years of Industry Experience

For more information about this report visit https://www.researchandmarkets.com/r/e9x4u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900